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Abstract
Objective To estimate the mortality and length of stay in the intensive care unit (ICU) attributable to
clinically important gastrointestinal bleeding in mechanically ventilated critically ill patients.
Design Three strategies were used to estimate the mortality attributable to bleeding in two multicentre
databases. The first method matched patients who bled with those who did not (matched cohort), using
duration of ICU stay prior to the bleed, each of six domains of the Multiple Organ Dysfunction Score
(MODS) measured 3 days prior to the bleed, APACHE II score, age, admitting diagnosis, and duration of
mechanical ventilation. The second approach employed Cox proportional hazards regression to match
bleeding and non-bleeding patients (model-based matched cohort). The third method, instead of matching,
derived estimates based on regression modelling using the entire population (regression method). Three
parallel analyses were conducted for the length of ICU stay attributable to clinically important bleeding.
Setting Sixteen Canadian university-affiliated ICUs.
Patients A total of 1666 critically ill patients receiving mechanical ventilation for at least 48 hours.
Measurements We prospectively collected data on patient demographics, APACHE II score,
admitting diagnosis, daily MODS, clinically important bleeding, length of ICU stay, and mortality.
Independent adjudicators determined the occurrence of clinically important gastrointestinal bleeding,
defined as overt bleeding in association with haemodynamic compromise or blood transfusion.
Results Of 1666 patients, 59 developed clinically important gastrointestinal bleeding. The mean
APACHE II score was 22.9 ± 8.6 among bleeding patients and 23.3 ± 7.7 among non-bleeding
patients. The risk of death was increased in patients with bleeding using all three analytic approaches
(matched cohort method: relative risk [RR] = 2.9, 95% confidence interval (CI) = 1.6–5.5; model-based
matched cohort method: RR = 1.8, 95% CI = 1.1–2.9; and the regression method: RR = 4.1, 95% CI =
2.6–6.5). However, this was not significant for the adjusted regression method (RR = 1.0, 95% CI =
0.6–1.7). The median length of ICU stay attributable to clinically important bleeding for these three
methods, respectively, was 3.8 days (95% CI = –0.01 to 7.6 days), 6.7 days (95% CI = 2.7–10.7
days), and 7.9 days (95% CI = 1.4–14.4 days).
Conclusions Clinically important upper gastrointestinal bleeding has an important attributable
morbidity and mortality, associated with a RR of death of 1–4 and an excess length of ICU stay of
approximately 4–8 days.
Keywords critical care, gastrointestinal bleeding, length of stay, matching mortality, regression analysis, stress
ulceration
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Introduction
Major upper gastrointestinal bleeding is a well-recognized
complication of critical illness, prompting three decades of
randomized trials of stress ulcer prophylaxis [1]. Clinically
important upper gastrointestinal bleeding is defined as
macroscopic bleeding that results in haemodynamic instabil-
ity or the need for red blood cell transfusion [2,3]. In hetero-
geneous ICU patients, clinically important bleeding rates are
low, but high risk groups are those requiring mechanical ven-
tilation for longer than 48 hours [4] or those who have a
coagulopathy [2,4,5–7]. Histamine-2-receptor antagonists
reduce the incidence of clinically important bleeding from 4 to
2% in high risk mechanically ventilated patients [8].
Although early reports of stress ulcer bleeding demonstrated
the frequent need for emergency surgery and indicated a high
mortality rate [9], the impact of clinically important gastro-
intestinal bleeding in recent years appears to be more
modest. While randomized trials of prophylaxis have shown
that prophylaxis can reduce bleeding rates by up to 50%,
they have not shown a decrease in mortality or duration of
ICU stay [10]. Nevertheless, when events do occur, they may
still be serious. In a small, matched cohort study, we found a
trend toward a higher risk of mortality associated with clini-
cally important bleeding (RR = 1.14, 95% CI = 0.7–2.0), and
a trend toward an increased length of ICU stay of 6.5 days
(95% C = –12.3 to 25.3 days) [11].
The objectives of this study were to more precisely estimate
the attributable mortality and length of ICU stay in mechani-
cally ventilated patients who develop clinically important gas-
trointestinal bleeding. To better understand the influence of
different analytic methods on the estimation of burden of
illness, we used three statistical approaches. The rationale for
using three different methods is that the study objectives
involve estimation of bleeding-attributable mortality and
length of stay in the ICU, based on observational data.
Because the occurrence of bleeding is obviously not a ran-
domized event, comparison of patients with and without
bleeds is potentially subject to confounding and interaction
with other variables. Modelling the effects of these additional
variables is not straightforward, and there is not one ‘correct’
approach. We selected three methods that involve different
assumptions, each with advantages and disadvantages. Con-
sistency of the mortality and length of stay results between
methods would be an indication of their robustness to
assumptions, and hence would provide more confidence of
their validity.
Methods
Two multicentre databases were used for this analysis. The
first included 1200 patients mechanically ventilated for
≥ 48 hours enrolled in a double-blind, concealed randomized
trial of sucralfate versus ranitidine to determine rates of
gastrointestinal bleeding and ventilator-associated pneumo-
nia (VAP) [8]. Exclusion criteria were an admitting diagnosis
of gastrointestinal bleeding or pneumonia, gastrectomy, pre-
dicted survival < 72 hours, or more than two prior doses of
stress ulcer prophylaxis. For these analyses, we also
excluded patients who died, were discharged or had gastro-
intestinal bleeding in the first 48 hours; therefore, 1077
patients were included from this study.
The second database was from a prognosis study of 2252
patients who were prospectively followed to determine the
incidence and risk factors of clinically important bleeding [4].
Patients were ineligible if they had gastrectomy, facial trauma,
epistaxis, brain death, or gastrointestinal bleeding 48 hours
prior to admission. A subset of 64 of these patients con-
tributed to our preliminary analysis of attributable morbidity
and mortality of clinically important bleeding described earlier
[11]. For the current analyses, we excluded patients who
were not mechanically ventilated for at least 48 hours, and
those who died, were discharged or had gastrointestinal
bleeding within 48 hours following ICU admission; therefore,
589 patients were included from this study.
In total, we considered 1666 mechanically ventilated patients
from these two databases for analyses of the mortality and
length of ICU stay associated with clinically important bleed-
ing. In both studies, signs of overt gastrointestinal bleeding
included haematemesis, bloody nasogastric aspirate, melena
or haematochezia. Management was at the discretion of the
ICU team and endoscopy was performed when clinically indi-
cated. All relevant clinical, laboratory and diagnostic notes
and documents were reviewed in duplicate and indepen-
dently by a Bleeding Adjudication Committee using previ-
ously employed reproducible criteria [2,3].
We defined clinically important bleeding as overt bleeding
plus one of the following four features in the absence of other
causes. The first feature was a spontaneous drop of systolic
or diastolic blood pressure of 20 mmHg or more within
24 hours of upper gastrointestinal bleeding. Second, an
orthostatic increase in pulse rate of 20 beats per minute and
a decrease in systolic blood pressure of 10 mmHg. The third
feature was a decrease in haemoglobin of at least 2 g/dl
(20 g/l) in 24 hours and transfusion of 2 U packed red blood
cells within 24 hours of bleeding. The final feature was failure
of the haemoglobin to increase by at least the number of units
transfused minus 2 g/dl (20 g/l). That is, if 8 g/dl (80 g/l)
haemoglobin and 4 U packed cells were infused, the bleed
would be considered important if the haemoglobin did not
rise by at least 2 g/dl (20 g/l) to 10 g/dl (20 g/l).
Demographic data collected included patient characteristics,
admission diagnosis, and APACHE II score [12] and daily
MODS [13]. MODS combines measures of physiologic dys-
function in six domains: the cardiovascular system (heart
rate × right atrial pressure/mean arterial pressure), the
pulmonary system (PaO2/FiO2 ratio), the renal system (serum
creatinine), the hepatic system (serum bilirubin), the haemato-Critical Care    December 2001 Vol 5 No 6 Cook et al.
logic system (platelet count), and the central nervous system
(Glasgow Coma Score). These continuous variables com-
prise six domains; a score of 0 represents normal function,
and a score of 4 reflects marked physiologic derangement.
The scores in each domain provide a measure of dysfunction
in the system of interest, and the composite scores provide a
measure of global dysfunction each day in the ICU.
Analysis
We expressed continuous variables by the mean ± standard
deviation when they were normally distributed, or the median
and interquartile range (IQR) when they were not. Student’s t
test was used to compare continuous variables and the chi-
square test was used to compare proportions. To allow com-
parisons of attributable length of ICU stay in two databases,
we expressed ICU length of stay using medians and 95% CIs
[14], estimating the standard deviation as three-quarters of the
interquartile range [15]. All statistical tests were two-tailed.
To provide estimates of the mortality and length of ICU stay
attributable to clinically important bleeding, three statistical
methods (described in the following) were applied to both
databases. There were no significant differences in age, sex
or baseline APACHE II score between patients in the first and
second databases, and the results of the attributable mortality
and length of ICU stay associated with bleeding were similar
(P > 0.05). We therefore pooled the estimates from these
databases and provide overall results.
ICU mortality attributable to clinically
important bleeding
Matched cohort method
In the first approach, we matched individual patients who bled
with control patients who did not bleed, but were otherwise
similar with respect to their risk of death. We chose the vari-
ables for matching, and their order, based on prior studies and
physiologic rationale. We matched each patient with clinically
important bleeding with one non-bleeding patient according to
the following hierarchy: duration of ICU stay prior to the bleed,
MODS domains measured 3 days prior to the bleed (central
nervous system, renal, respiratory, haematologic, cardiovascu-
lar, and hepatic components separately) (± 1), baseline
APACHE II score (± 4 points), age (± 10 years), admitting
diagnosis, and duration of mechanical ventilation prior to the
bleed. If there was more than one match for a bleeding patient,
the control patient was selected by the best match according
to the matching hierarchy. Using this algorithm, we identified
matches for all bleeding patients. The RR of death and its
associated 95% CI was calculated using a stratified
Mantel–Haenszel RR where each stratum was a matched pair
[16]. We then estimated the absolute risk of mortality attrib-
uted to bleeding as the mortality in patients with bleeding
minus the mortality in the matched patients without bleeding.
CIs for the absolute attributable mortality and the statistical
test determining whether it was significantly different from zero
was based on a matched analysis [17].
Model-based matched cohort method
The second approach also relied on matching. However, vari-
ables for the match were empirically determined from the
databases. We performed a stepwise Cox proportional
hazards regression analysis [18] among patients who did not
bleed, using risk of death as the dependent variable. We con-
sidered variables for matching in the order indicated by the
regression analysis. Variables that were significant in the
stepwise procedure at the P < 0.10 level were considered for
the final model. For the first database, these variables were
age, diagnosis, duration of ventilation, and MODS (cardiovas-
cular, pulmonary, renal, haematologic and central nervous
system components). For the second database, the variables
were age, baseline APACHE II score, diagnosis, duration of
ventilation, and MODS (cardiovascular, pulmonary, renal and
central nervous system components).
We censored all patients who were alive in the ICU for longer
than 28 days. If patients were transferred to another ward or
hospital, or discharged home, we assumed that they were
alive and also censored them at 28 days. Patients transferred
to another ICU or who were withdrawn from the study were
censored on their last day of follow-up or at 28 days,
whichever came first. The beta coefficients from the final
model were used to create a score that was then used to
match each bleeding patient with a non-bleeding patient. In
the case of a tie, we used the same approach as already
described for the matched cohort method. The absolute
attributable mortality was also calculated as described for the
matched cohort method.
Regression method
The third approach did not use matching. We performed Cox
proportional hazards regression on all patients, using risk of
death as the dependent variable. We considered the same
variables described in the model-based matched cohort analy-
sis, and our approach to censoring was identical. Independent
variables were measured at baseline (age, baseline APACHE
II score, and admitting diagnosis) and in a time-dependent
manner (ventilation status, six MODS domains, and bleeding
status). We calculated the RR of mortality associated with
bleeding, adjusted for the other independent variables. We
evaluated the assumption of proportional hazards of mortality
risk that was attributable to bleeding by including the interac-
tion of bleeding with time as an additional predictor.
Length of ICU stay attributable to clinically
important bleeding
We used the same three approaches to calculate the attribut-
able length of stay associated with clinically important bleed-
ing as we did for mortality.
Matched cohort method
For the matched cohort approach, we matched on mortality
status first, in addition to the variables described in the attribut-
able mortality analysis. We estimated the absolute attributablelength of ICU stay as the median difference in the length of
ICU stay between each matched pair, with a 95% CI [17].
We then repeated the matching process and estimation of
length of ICU stay but without matching on mortality status.
Model-based matched cohort method
In the second approach for estimating attributable length of
ICU stay, the dependent variable was rate of discharge or
death. We censored all patients who were transferred to
another ICU, withdrew from the study or were followed for
99 days. The beta coefficients from the final model were used
to create a score that was then used to match each bleeding
patient with a non-bleeding patient. In the case of a tie, we
used the same approach as described for the matched
cohort mortality analysis. This matching procedure was con-
ducted twice: considering and then not considering mortality
as a possible predictor in the regression.
Regression method
For the third approach, we performed a Cox proportional
hazards regression as previously described, using time to dis-
charge or death as the dependent variable, censoring patients
as already indicated. We then adjusted for all other independent
variables and report the median attributable length of stay [19].
Results
Among 1666 mechanically ventilated patients, 59 had clinically
important gastrointestinal bleeding (3.5%, 95% CI =
2.7–4.6%). Bleeding and non-bleeding patients were similar in
age (mean ± SD: 62.5 ± 15.0 years versus 59.0 ± 17.7 years,
P= 0.14), sex (32.2% versus 39.8% female, P= 0.24), and
APACHE II score (mean ± SD: 22.9 ± 8.6 versus 23.3 ± 7.7,
P= 0.67). There was a significant difference in the length of ICU
stay (median, 26 days [IQR = 18–38] versus 8 days
[IQR = 5–15], P< 0.0001) and mortality (45.8% versus 20.9%,
P< 0.0001) between bleeding and non-bleeding patients.
Attributable mortality
The results are reported in Table 1. The crude comparison of
bleeding versus non-bleeding patients yielded a RR of 2.2
(95% CI = 1.6–2.9) and an absolute risk of 24.0% (95%
CI = 11.3–36.6). Figure 1 shows the survival curve of
mechanically ventilated patients who have clinically important
bleeding compared with those who do not. Using the matched
cohort method, the RR of mortality attributable to clinically
important gastrointestinal bleeding was significant (RR = 2.9,
95% CI = 1.6–5.5). The mortality attributable to bleeding was
also statistically significant using the model-based matched
cohort method (RR = 1.8, 95% CI = 1.1–2.9). The attributable
mortality using the regression method was RR = 4.1 (95%
CI = 2.6–6.5) without adjustment for covariates, and RR = 1.0
(95% CI = 0.6–1.7) after adjustment.
We also tested whether the risk of mortality attributable to
bleeding was constant over time, using the unadjusted
regression method. We found that patients who bled earlier
in their ICU stay had a lower risk of dying than patients who
bled later (P = 0.02): the RR of mortality associated with clini-
cally important bleeding was 0.4 (95% CI = 0.06–2.0) at
2 weeks, 1.6 (95% CI = 0.6–4.0) at 3 weeks, and 7.4 (95%
CI = 1.7–32.2) at 4 weeks. One overall estimate of risk of
death associated with bleeding in the regression method may
therefore be misleading. Note, however, that the other two
methods (matched cohort and model-based matched cohort)
also calculate overall risk measures of the bleeding effect, but
do not take into account or examine potential variation in risk
over time. In view of the findings in the regression method,
the overall results of the other two methods, which do not
take time into account, may also be potentially misleading.
Attributable length of ICU stay
Figure 2 shows the distribution of length of ICU stay among
bleeding and non-bleeding patients using all 1666 patients
(P < 0.0001). The crude comparison of bleeding and non-
bleeding patients yielded an attributable length of ICU stay of
17.2 days (95% CI = 13.2–21.3 days) overall (Table 2).
Using the matched cohort method, we found that the attribut-
able length of ICU stay for patients with clinically important
bleeding was not significantly increased, at 0.6 days (95%
CI = –5.1 to 6.3 days) in non-survivors and 3.8 days (95%
CI = –0.01 to 7.6 days) overall. The attributable ICU stay
using the model-based matched cohort method was 5.1 days
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Table 1
Intensive care unit (ICU) mortality attributable to clinically important gastrointestinal bleeding
ICU mortality Relative risk (95% confidence interval) Absolute risk (95% confidence interval)
Crude comparison 2.2 (1.6–2.9) 24.0 (11.3–36.6)
Matched cohort method 2.9 (1.6–5.5) 30.3 (15.2–45.3)
Model-based matched cohort method 1.8 (1.1–2.9) 20.3 (4.3–36.4)
Regression method 4.1 (2.6–6.5) –
Adjusted* 1.0 (0.6–1.7) –
The model-based matched cohort probably yields the best estimate of the attributable mortality. See Table 3 for advantages and disadvantages of
these methods. * Adjusted for age, APACHE II score, admitting diagnosis, duration of ventilation, Multiple Organ Dysfunction Score, and bleeding
status.(95% CI = 0.3–9.9 days) incorporating mortality as a possi-
ble predictor of length of stay, and 6.7 days (95%
CI = 2.7–10.7 days) overall, indicating a significant increase.
The regression method showed an increase in ICU length of
stay of 7.9 days (95% CI = 1.4–14.4 days) without adjusting
for other variables. After adjusting for age, APACHE II score,
admitting diagnosis, ventilation status, and six MODS
domains, the ICU stay attributable to bleeding by the regres-
sion method was 6.2 days (95% CI = 1.0–11.4 days).
Discussion
We found that clinically important bleeding was associated
with an increase in mortality (absolute risk increase, 20–30%;
RR increase, 1–4) and an increased length of ICU stay
(approximately 4–8 days) using three different analytic
methods. We used two different control groups for matching
in the two matched cohort methods to improve the robust-
ness of the results [20]. To control for age, illness severity,
admitting diagnosis, ventilation status, bleeding status and
organ dysfunction, we used multivariate methods. We consid-
ered the potential bias of ICU-acquired confounding factors
[21] by controlling for mechanical ventilation status and organ
dysfunction in all six MODS domains as time-dependent vari-
ables until 3 days prior to the bleed. We used the RR to gen-
erate more clinically interpretable and conservative
associations than those expressed by odds ratios [22]. We
presented median rather than mean durations of ICU stay to
avoid inflated estimates of length of stay [23]. We used
objective criteria for clinically important upper gastrointestinal
bleeding, which were determined in duplicate by blinded
adjudicators unaware of this study hypothesis [24].
Other studies have estimated the attributable mortality and
length of ICU stay for complications of critical illness such as
catheter-related infection [21,25–27]. Interpreting such
studies requires examination of issues such as population
characteristics, case definition, and statistical strategies. In
considering statistical strategies to determine the attributable
mortality of another ICU outcome (VAP), two basic
approaches have been used: logistic regression and compar-
ative methods (with or without matching). The regression
Critical Care    December 2001 Vol 5 No 6 Cook et al.
Table 2
Length of intensive care unit (ICU) stay attributable to clinically
important gastrointestinal bleeding
ICU length of stay  Median difference 
(days) (95% confidence interval)
Crude comparison
Non-survivors 14.0 (8.6–19.4)
Overall 17.2 (13.2–21.3)
Matched cohort method
Non-survivors 0.6 (–5.1–6.3)
Overall 3.8 (–0.01–7.6)
Model-based matched cohort method
Matching on mortality status 5.1 (0.3–9.9)
Overall 6.7 (2.7–10.7)
Regression method
Unadjusted 7.9 (1.4–14.4)
Adjusted* 6.2 (1.0–11.4)
The model-based matched cohort probably yields the best estimate of
the length of ICU stay. See Table 3 for advantages and disadvantages
of these methods. * Adjusted for age, APACHE II score, admitting
diagnosis, duration of ventilation, Multiple Organ Dysfunction Score,
and bleeding status.
Figure 1
The survival curves for patients with and without clinically important
gastrointestinal bleeding. ICU, intensive care unit; d, days.
Figure 2
The distributions of the length of intensive care unit (ICU) stay for
patients with and without clinically important gastrointestinal bleeding.
d, days.method commonly used to determine the attributable mortality
of a condition such as VAP considers mortality status as a
dependent variable, then selects independent variables (includ-
ing VAP and other events) to test their association with mortal-
ity. Regression analysis can potentially yield distorted
associations by selection of only a subset of variables that influ-
ence mortality risk, and by omission of key variables that would
alter the findings if they were included. Nevertheless, in suffi-
ciently powered studies, VAP was found to be an independent
predictor of mortality after adjusting for other characteristics
and ICU-acquired events using regression analysis [28–31].
In addition to regression methods, studies of the attributable
morbidity and mortality of VAP have been conducted using
comparative methods. In addition to issues of population dif-
ferences and case definition [32], another explanation for the
discordant results is the analytic approaches used. These
approaches include unmatched crude comparison of patients
with and without VAP [33], simple matching of patients with
and without VAP based on baseline characteristics [34],
matching of patients based on baseline characteristics and
discharge diagnosis [35], and matched cohort analyses that
incorporate baseline characteristics and time-dependent vari-
ables that could influence outcome [32,36–38].
Our analysis of the attributable morbidity and mortality of clini-
cally important gastrointestinal bleeding used both compari-
son and regression methods. In the absence of a
well-accepted single approach or guidelines for an optimal
analysis, we summarize the advantages and disadvantages of
the methods used to estimate the attributable mortality and
length of ICU stay associated with clinically important bleed-
ing (Table 3). The crude comparison method ignores the influ-
ence of confounding factors and inevitably yields inaccurate
estimates. The three other approaches (the matched cohort
method, the model-based matched cohort method, and the
regression method) are superior to a crude comparison
method because adjustment for potentially important con-
founding factors is more likely to yield valid estimates.
Although the matched cohort method is founded on biologic
rationale to match patients, clinical judgement may some-
times fail to adjust for all important determinants of outcome.
In contrast, both the model-based matched cohort method
and the regression method allow for adjustment of additional
potentially important confounders. Moreover, they both can
be customized to the database in which they are developed.
Finally, there is the issue of the effect of bleeding over time.
The matched cohort method and model-based matched
cohort method both use the Mantel–Haenszel technique,
which is founded on an assumption of constant odds over
time. The initial regression method used Cox proportional
hazards to estimate the risk of mortality, which generates
valid estimates if the assumption of proportional hazard holds
(e.g. if the risk is stable over time). However, when we tested
whether the risk of mortality attributable to bleeding was con-
stant over time using the regression model, we found that it
was not. When bleeding occurred in the first 3 weeks of ICU
stay, there was a trend toward a decreased risk of death in
bleeding patients compared with non-bleeding patients.
When bleeding occurred 4 weeks or longer following ICU
admission, the risk of death was significantly increased in
bleeding  patients compared with non-bleeding patients. This
interesting finding may reflect the more serious pathophysiology
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Table 3
Advantages and disadvantages of different approaches to estimating attributable mortality and length of intensive care unit stay
Method Advantages Disadvantages
Crude comparison Simple Ignores influence of confounding factors, possibly 
yielding biased estimates
Matched cohort method Integrates biologic rationale for matching  May fail to adjust for important confounding factors, 
patients; can be used in multiple databases;  possibly yielding biased estimates; compared with 
compared with regression method, avoids bias  regression model, event rate over time is not 
if event rate is not constant over time considered
Model-based matched cohort Analysis customized to the database; compared  Compared with matched cohort method, chance 
method with crude or matched cohort method, more  associations may generate biased estimates due to 
likely to adjust for important confounding factors;  ‘overmatching’; compared with regression model, 
compared with regression method, avoids bias  event rate over time is not considered
if event rate is not constant over time
Regression method Analysis customized to the database; uses all  Complex; compared with matched cohort method, 
patient data; considers patterns of events and  chance associations may generate biased estimates 
predictors over time and generates most  due to ‘overmatching’; biased estimates may also 
precise estimates if event rate is constant  result if event rate is not constant over time
over time
The advantages and disadvantages of several approaches to estimating the attributable mortality and length of intensive care unit stay associated
with clinically important bleeding are presented (a crude comparison of bleeding and non-bleeding patients, and the three methods used in these
analyses).of late onset bleeding due to a longstanding ischaemic gas-
tropathy, which is often considered a manifestation of multi-
ple organ dysfunction [13].
In summary, in this population of 1666 ICU patients ventilated
for > 48 hours, we have demonstrated that clinically impor-
tant gastrointestinal bleeding is associated with a significant
increase in attributable mortality (full range of RRs, 1–4) and
length of ICU stay (approximately 4–8 days). These results
build on previous work estimating the clinical and economic
consequences of bleeding in which we used a hierarchical
matched cohort study of 64 patients. We previously found a
trend toward an increased risk of mortality (RR = 1.14, 95%
CI = 0.7–2.0), and a trend toward an increased length of ICU
stay of 6.5 days (95% CI = –12.3 to 25.3 days) associated
with clinically important bleeding [11]. We also found that
each episode resulted in a mean of seven additional haema-
tology tests, 11 blood product transfusions, and 24 days of
treatment, resulting in an overall cost of clinically important
bleeding of $12,000. This analysis is limited in that patients
who were admitted to ICU with a diagnosis of pneumonia or
patients who had two or more doses of prophylaxis were
excluded from the first database. Although it possible that the
attributable morbidity and mortality of clinically important
bleeding in such patients may differ from other ICU patients
ventilated for at least 48 hours, this seems very unlikely. Of
course, these results do not show that bleeding events them-
selves directly lead to increased length of stay or death; thus,
causation cannot be inferred from these analyses.
In two multicentre studies, the Canadian Critical Care Trials
Group has found that clinically important bleeding occurs in
4% of mechanically ventilated patients [4,8]. However, bleed-
ing rates vary; 2.4% of patients had macroscopic bleeding in
one study in the Netherlands, in which all patients received
selective digestive decontamination, dopamine, nitroglycerin,
and ketanserin while mechanically ventilated, and tapering
doses of dexamethasone [39]. Prevention may be unneces-
sary in populations in which clinically important bleeding is
documented to be very rare, [40], and thus bleeding prophy-
laxis strategies may need to be customized to different set-
tings. A formal cost-effectiveness analysis would best
address the impact of alternative stress ulcer prophylaxis poli-
cies including targeted prevention for patients at highest risk,
which requires accurate estimates and a plausible range of
estimates for the target event. The analyses we report for the
attributable length of ICU stay and mortality associated with
clinically important bleeding can thus be integrated with evi-
dence about incidence, risk factors, and the advantages and
disadvantages of various preventive strategies, to better
understand the consequences of different approaches to
stress ulcer prophylaxis.
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